S&P 500 Futures
(-0.02%) 5 307.00 points
Dow J Futures
(0.03%) 40 156 points
Nasdaq Futures
(-0.03%) 18 499 points
Oil
(1.62%) $82.67
Gas
(0.12%) $1.720
Gold
(0.91%) $2 232.80
Silver
(-0.18%) $24.71
Platinum
(0.44%) $913.70
USD/EUR
(0.36%) $0.927
USD/NOK
(0.60%) $10.83
USD/GBP
(0.12%) $0.792
USD/RUB
(-0.09%) $92.36

Realtime updates for Karyopharm Therapeutics [KPTI]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
25.00%
return -15.90%
SELL
40.00%
return -2.40%
Last Updated27 Mar 2024 @ 16:00

6.47% $ 1.480

BUY 61430 min ago

@ $1.418

Issued: 14 Feb 2024 @ 15:43


Return: 4.37%


Previous signal: Feb 13 - 12:41


Previous signal: Sell


Return: 12.54 %

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases...

Stats
Today's Volume 1.28M
Average Volume 1.76M
Market Cap 170.30M
EPS $0 ( 2024-02-29 )
Next earnings date ( $-0.330 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -1.180
ATR14 $0.00600 (0.41%)
Insider Trading
Date Person Action Amount type
2024-03-05 Paulson Richard A. Sell 3 573 Common Stock
2024-02-29 Rangwala Reshma Sell 15 667 Common
2024-03-01 Rangwala Reshma Sell 5 969 Common
2024-02-29 Poulton Stuart Sell 16 311 Common
2024-03-01 Poulton Stuart Sell 6 155 Common
INSIDER POWER
70.40
Last 99 transactions
Buy: 2 857 011 | Sell: 548 860

Volume Correlation

Long: -0.23 (neutral)
Short: 0.89 (strong)
Signal:(63.089) Same movement expected

Karyopharm Therapeutics Correlation

10 Most Positive Correlations
RMRM0.914
GAINL0.87
10 Most Negative Correlations
BRAG-0.833
EM-0.806
AVTE-0.804
ARCE-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Karyopharm Therapeutics Correlation - Currency/Commodity

The country flag -0.06
( neutral )
The country flag 0.10
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.09
( neutral )

Karyopharm Therapeutics Financials

Annual 2023
Revenue: $146.03M
Gross Profit: $140.56M (96.25 %)
EPS: $-1.250
Q4 2023
Revenue: $33.75M
Gross Profit: $32.18M (95.37 %)
EPS: $-0.360
Q3 2023
Revenue: $36.01M
Gross Profit: $35.10M (97.47 %)
EPS: $-0.300
Q2 2023
Revenue: $37.58M
Gross Profit: $36.39M (96.82 %)
EPS: $-0.290

Financial Reports:

No articles found.

Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators